The product will be manufactured at the Company’s Oral Dosage Facility at Bangalore and will be marketed by Strides Pharma Inc.
Strides Shasun Limited has said that it’s wholly owned subsidiary Strides Pharma Global Pte. Limited has received approval for Piroxicam capsules 10mg and 20mg from the United States Food & Drug Administration (US FDA). The product received approval within ten months under the GDUFA regime. According to IMS data, the US market for Piroxicam capsules 10mg and 20mg is approximately USD 11 Million. The product will be manufactured at the Company’s Oral Dosage Facility at Bangalore and will be marketed by Strides Pharma Inc.
GET FREE STOCK CASH TIPS AND INDIAN STOCK MARKET RECOMMENDATIONS CALL ON 9644405056!
in the US Market. Piroxicam is a non-steroidal anti-inflammatory agent with analgesic and antipyretic activity. Piroxicam is indicated for the symptomatic relief of rheumatoid arthritis, osteoarthritis or ankylosing spondylitis. Meanwhile, shares of the company were trading at Rs 775.55 apiece, down 1.27 percent from the previous close at 11:04 hours on BSE.
For more visit us at www.ripplesadvisory.com
Or mail us here: email@example.com
Contact us on (+91) 9644405056 (Quick Free Trials)
Customer Care Service: (+0731) 242-7007